Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Head and Neck Squamous Cell Carcinoma (HNSCC): early-phase trial registry
10 of 15 indexed Head and Neck Squamous Cell Carcinoma (HNSCC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 10 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Head and Neck Squamous Cell Carcinoma (HNSCC): 15 US clinical trials tracked, 10 recruiting.
Head and Neck Squamous Cell Carcinoma (HNSCC) is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is RTOG Foundation, running 1 of these trials.
Enrollment posture brief
Registry condition head-and-neck-squamous-cell-carcinoma-hnscc
OPEN 10 | RECR 67% | LATE 0 | EARLY 14 | RANK #1140 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Head and Neck Squamous Cell Carcinoma (HNSCC) lists 10 open slots (67% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Head and Neck Squamous Cell Carcinoma (HNSCC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Head and Neck Squamous Cell Carcinoma (HNSCC) is recruiting above its size-band peers.
10 of 15 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Head and Neck Squamous Cell Carcinoma (HNSCC) trials is spread across many organizations.
RTOG Foundation accounts for 1 of 15 trials (6.7%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Head and Neck Squamous Cell Carcinoma (HNSCC) enrolment sits around 120 participants.
Median target enrolment is 120 among the 15 trials that report a genuine target (sentinel values excluded). 7 of those (46.7%) plan for fewer than 100 participants.
-
Head and Neck Squamous Cell Carcinoma (HNSCC) research is mostly interventional.
15 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
NCT05176483
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
Inhibrx Biosciences
NCT06295731
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology
NCT03556228
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals
NCT05985655
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma
NCT07227168
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
NCT06769698
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
Dan Zandberg
NCT04080804
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
LG Chem
NCT06332755
Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery
Wake Forest University Health Sciences
NCT06607406
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America
NCT06943521
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
NCT04083599
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
RTOG Foundation
NCT03546582
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
Boehringer Ingelheim
NCT05249426
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences
NCT05891171
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
NCT04215978
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Head and Neck Squamous Cell Carcinoma (HNSCC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Head and Neck Squamous Cell Carcinoma (HNSCC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Head and Neck Squamous Cell Carcinoma (HNSCC) page
15 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Head and Neck Squamous Cell Carcinoma (HNSCC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- RTOG Foundation sponsors the most Head and Neck Squamous Cell Carcinoma (HNSCC) trials on record, review their full trial history before evaluating a specific study. See RTOG Foundation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Head and Neck Squamous Cell Carcinoma (HNSCC) condition card totals 15 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.